TTK Healthcare Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: June 25, 2025, 8:01 pm

Market Cap	1,815 Cr.
Current Price	1,284
High / Low	1,923/991
Stock P/E	25.5
Book Value	754
Dividend Yield	0.78 %
ROCE	9.25 %
ROE	6.89 %
Face Value	10.0
PEG Ratio	2.13

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for TTK Healthcare Ltd

Competitors of TTK Healthcare Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Lactose (India) Ltd	141 Cr.	100	247/84.3	27.3	41.7	0.00 %	12.9 %	9.75 %	10.0
MPS Pharmaa Ltd	5.48 Cr.	2.87	4.33/2.50		0.57	0.00 %	9.79 %	59.0 %	10.0
Gujarat Themis Biosyn Ltd	2,663 Cr.	244	390/192	50.6	20.5	0.27 %	45.0 %	33.8 %	1.00
Gujarat Terce Laboratories Ltd	41.4 Cr.	55.8	94.9/44.5		8.73	0.00 %	41.5 %	14.4 %	10.0
Gujarat Inject (Kerala) Ltd	37.7 Cr.	25.7	29.1/13.1	37.0	6.83	0.00 %	13.5 %	11.0 %	10.0
Industry Average	18,566.61 Cr	1,158.58		103.22	194.43	0.31%	16.65%	15.19%	6.18

All Competitor Stocks of TTK Healthcare Ltd

Quarterly Result

Metric	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	159	193	170	183	180	202	186	184	181	208	198	205	190
Expenses	154	189	166	174	165	192	176	179	169	201	190	197	178
Operating Profit	5	4	4	8	15	10	10	5	12	7	8	8	12
OPM %	3%	2%	2%	5%	8%	5%	5%	3%	7%	3%	4%	4%	6%
Other Income	12	606	13	12	12	15	16	16	16	37	18	18	13
Interest	1	3	1	1	1	1	1	0	1	1	1	1	1
Depreciation	3	3	3	3	3	3	3	3	3	2	2	2	2
Profit before tax	12	604	13	16	23	21	22	18	24	41	23	23	22
Tax %	13%	1%	23%	26%	27%	24%	26%	27%	25%	23%	26%	26%	26%
Net Profit	11	601	10	12	17	16	16	13	18	32	17	17	16
EPS in Rs	7.52	425.23	7.01	8.49	11.99	11.09	11.33	9.12	12.93	22.35	12.17	11.84	11.43

Last Updated: May 31, 2025, 7:27 am

Below is a detailed analysis of the quarterly data for TTK Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Sales, as of Mar 2025, the value is 190.00 Cr.. The value appears to be declining and may need further review. It has decreased from 205.00 Cr. (Dec 2024) to 190.00 Cr., marking a decrease of 15.00 Cr..
For Expenses, as of Mar 2025, the value is 178.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 197.00 Cr. (Dec 2024) to 178.00 Cr., marking a decrease of 19.00 Cr..
For Operating Profit, as of Mar 2025, the value is 12.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Dec 2024) to 12.00 Cr., marking an increase of 4.00 Cr..
For OPM %, as of Mar 2025, the value is 6.00%. The value appears strong and on an upward trend. It has increased from 4.00% (Dec 2024) to 6.00%, marking an increase of 2.00%.
For Other Income, as of Mar 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 18.00 Cr. (Dec 2024) to 13.00 Cr., marking a decrease of 5.00 Cr..
For Interest, as of Mar 2025, the value is 1.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 1.00 Cr..
For Depreciation, as of Mar 2025, the value is 2.00 Cr.. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 2.00 Cr..
For Profit before tax, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 23.00 Cr. (Dec 2024) to 22.00 Cr., marking a decrease of 1.00 Cr..
For Tax %, as of Mar 2025, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Dec 2024) which recorded 26.00%.
For Net Profit, as of Mar 2025, the value is 16.00 Cr.. The value appears to be declining and may need further review. It has decreased from 17.00 Cr. (Dec 2024) to 16.00 Cr., marking a decrease of 1.00 Cr..
For EPS in Rs, as of Mar 2025, the value is 11.43. The value appears to be declining and may need further review. It has decreased from 11.84 (Dec 2024) to 11.43, marking a decrease of 0.41.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 3:38 pm

Metric	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Sales	416	483	519	528	578	628	646	476	599	725	753	801
Expenses	396	453	478	489	535	578	617	457	577	694	715	767
Operating Profit	20	30	40	38	43	50	28	19	22	31	37	35
OPM %	5%	6%	8%	7%	7%	8%	4%	4%	4%	4%	5%	4%
Other Income	6	7	6	6	8	8	9	28	42	643	63	85
Interest	3	4	3	3	5	3	3	2	3	5	3	3
Depreciation	3	6	7	12	15	15	14	13	13	13	13	8
Profit before tax	20	26	36	29	30	39	19	32	48	657	84	108
Tax %	37%	39%	36%	36%	40%	38%	37%	-44%	13%	3%	25%	25%
Net Profit	12	16	23	19	18	24	12	46	42	640	63	82
EPS in Rs	15.95	20.81	29.19	24.13	12.86	17.25	8.72	32.87	29.43	452.72	44.47	57.79
Dividend Payout %	25%	22%	17%	21%	39%	29%	34%	18%	34%	2%	22%	17%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024	2024-2025
YoY Net Profit Growth (%)	33.33%	43.75%	-17.39%	-5.26%	33.33%	-50.00%	283.33%	-8.70%	1423.81%	-90.16%	30.16%
Change in YoY Net Profit Growth (%)	0.00%	10.42%	-61.14%	12.13%	38.60%	-83.33%	333.33%	-292.03%	1432.51%	-1513.97%	120.31%

TTK Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	5%
5 Years:	4%
3 Years:	10%
TTM:	6%

Compounded Profit Growth
10 Years:	16%
5 Years:	42%
3 Years:	22%
TTM:	13%

Stock Price CAGR
10 Years:	4%
5 Years:	24%
3 Years:	20%
1 Year:	-13%

Return on Equity
10 Years:	23%
5 Years:	26%
3 Years:	29%
Last Year:	7%

Last Updated: Unknown

Balance Sheet

Last Updated: June 16, 2025, 11:10 am

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	8	8	8	8	14	14	14	14	14	14	14	14
Reserves	99	110	128	150	219	237	235	281	316	939	987	1,051
Borrowings	32	42	38	23	47	29	30	19	22	27	23	24
Other Liabilities	102	115	128	104	127	136	152	180	207	189	177	192
Total Liabilities	240	275	303	285	407	416	431	494	559	1,170	1,201	1,281
Fixed Assets	54	52	106	99	110	98	89	85	80	71	75	81
CWIP	2	46	1	0	1	2	9	0	0	3	1	0
Investments	0	0	10	9	9	13	9	13	15	13	13	11
Other Assets	184	177	185	177	288	304	325	395	463	1,083	1,112	1,189
Total Assets	240	275	303	285	407	416	431	494	559	1,170	1,201	1,281

Below is a detailed analysis of the balance sheet data for TTK Healthcare Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 14.00 Cr..
For Reserves, as of Mar 2025, the value is 1,051.00 Cr.. The value appears strong and on an upward trend. It has increased from 987.00 Cr. (Mar 2024) to 1,051.00 Cr., marking an increase of 64.00 Cr..
For Borrowings, as of Mar 2025, the value is 24.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 23.00 Cr. (Mar 2024) to 24.00 Cr., marking an increase of 1.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 192.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 177.00 Cr. (Mar 2024) to 192.00 Cr., marking an increase of 15.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 1,281.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,201.00 Cr. (Mar 2024) to 1,281.00 Cr., marking an increase of 80.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 81.00 Cr.. The value appears strong and on an upward trend. It has increased from 75.00 Cr. (Mar 2024) to 81.00 Cr., marking an increase of 6.00 Cr..
For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
For Investments, as of Mar 2025, the value is 11.00 Cr.. The value appears to be declining and may need further review. It has decreased from 13.00 Cr. (Mar 2024) to 11.00 Cr., marking a decrease of 2.00 Cr..
For Other Assets, as of Mar 2025, the value is 1,189.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,112.00 Cr. (Mar 2024) to 1,189.00 Cr., marking an increase of 77.00 Cr..
For Total Assets, as of Mar 2025, the value is 1,281.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,201.00 Cr. (Mar 2024) to 1,281.00 Cr., marking an increase of 80.00 Cr..

Notably, the Reserves (1,051.00 Cr.) exceed the Borrowings (24.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Month		Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023
Cash from Operating Activity +	13	39	37	18	25	17	20	96	45	-25	-5	-4
Cash from Investing Activity +	-15	-49	-27	5	-22	10	-13	-77	-30	32	28	20
Cash from Financing Activity +	2	3	-11	-23	-7	-31	-10	-17	-10	-12	-22	-18
Net Cash Flow	0	-7	-0	0	-4	-4	-4	2	5	-6	2	-2

Free Cash Flow

Month	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-12.00	-12.00	2.00	15.00	-4.00	21.00	-2.00	0.00	0.00	4.00	14.00	11.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	34	34	34	33	24	35	47	43	46	33	46	42
Inventory Days	52	64	62	66	65	80	77	101	123	102	89	105
Days Payable	55	56	50	53	100	130	101	121	170	134	116	110
Cash Conversion Cycle	31	41	46	46	-11	-16	22	23	-2	1	19	36
Working Capital Days	-8	-12	-14	-22	-9	-1	10	13	-18	-15	17	62
ROCE %	21%	17%	20%	23%	18%	15%	15%	8%	6%	8%	10%	9%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	74.56%	74.56%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%	74.57%
FIIs	2.40%	2.34%	2.37%	2.32%	2.38%	2.40%	1.85%	1.85%	1.85%	1.87%	1.90%	1.90%
DIIs	2.40%	2.51%	2.22%	2.18%	2.99%	3.27%	3.23%	3.13%	1.14%	1.14%	1.14%	1.14%
Public	20.64%	20.59%	20.84%	20.95%	20.07%	19.76%	20.37%	20.46%	22.45%	22.44%	22.39%	22.39%
No. of Shareholders	15,817	15,228	14,617	14,995	15,818	16,109	15,672	16,651	17,221	16,930	15,762	15,780

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Axis ELSS Tax Saver Fund	172,386	0.08	25.52	172,386	2025-04-22 15:56:52	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23	Mar 22	Mar 21
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	57.79	44.47	452.72	29.43	32.87
Diluted EPS (Rs.)	57.79	44.47	452.72	29.43	32.87
Cash EPS (Rs.)	63.69	53.71	461.79	38.34	42.08
Book Value[Excl.RevalReserv]/Share (Rs.)	753.73	705.23	671.59	230.16	205.40
Book Value[Incl.RevalReserv]/Share (Rs.)	753.73	708.35	674.71	233.28	208.52
Dividend / Share (Rs.)	10.00	10.00	10.00	10.00	6.00
Revenue From Operations / Share (Rs.)	567.22	532.75	513.16	424.08	336.91
PBDIT / Share (Rs.)	75.07	70.72	56.39	27.01	20.70
PBIT / Share (Rs.)	69.18	61.48	47.33	18.11	11.49
PBT / Share (Rs.)	76.67	59.53	43.62	17.58	16.01
Net Profit / Share (Rs.)	57.79	44.47	452.72	29.43	32.87
PBDIT Margin (%)	13.23	13.27	10.98	6.36	6.14
PBIT Margin (%)	12.19	11.54	9.22	4.26	3.41
PBT Margin (%)	13.51	11.17	8.50	4.14	4.75
Net Profit Margin (%)	10.18	8.34	88.22	6.94	9.75
Return on Networth / Equity (%)	7.66	6.30	67.41	12.78	16.00
Return on Capital Employeed (%)	9.13	8.64	6.97	7.56	5.31
Return On Assets (%)	6.37	5.23	54.67	7.44	9.39
Total Debt / Equity (X)	0.02	0.02	0.02	0.06	0.06
Asset Turnover Ratio (%)	0.64	0.63	0.83	1.14	1.03
Current Ratio (X)	5.23	5.50	5.06	2.03	1.99
Quick Ratio (X)	4.72	5.01	4.66	1.68	1.61
Inventory Turnover Ratio (X)	1.90	1.91	2.23	1.92	1.38
Dividend Payout Ratio (NP) (%)	0.00	22.48	2.20	20.38	9.12
Dividend Payout Ratio (CP) (%)	0.00	18.61	2.16	15.65	7.12
Earning Retention Ratio (%)	0.00	77.52	97.80	79.62	90.88
Cash Earning Retention Ratio (%)	0.00	81.39	97.84	84.35	92.88
Interest Coverage Ratio (X)	31.91	36.27	15.21	11.79	17.10
Interest Coverage Ratio (Post Tax) (X)	21.38	23.81	9.53	5.95	17.77
Enterprise Value (Cr.)	929.27	1342.13	639.44	918.42	488.79
EV / Net Operating Revenue (X)	1.16	1.78	0.88	1.53	1.03
EV / EBITDA (X)	8.76	13.43	8.03	24.06	16.71
MarketCap / Net Operating Revenue (X)	2.11	2.78	2.01	1.96	1.47
Retention Ratios (%)	0.00	77.51	97.79	79.61	90.87
Price / BV (X)	1.59	2.10	1.54	3.60	2.41
Price / Net Operating Revenue (X)	2.11	2.78	2.01	1.96	1.47
EarningsYield	0.04	0.02	0.43	0.03	0.06

After reviewing the key financial ratios for TTK Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
For Diluted EPS (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
For Cash EPS (Rs.), as of Mar 25, the value is 63.69. This value is within the healthy range. It has increased from 53.71 (Mar 24) to 63.69, marking an increase of 9.98.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 753.73. It has increased from 705.23 (Mar 24) to 753.73, marking an increase of 48.50.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 753.73. It has increased from 708.35 (Mar 24) to 753.73, marking an increase of 45.38.
For Dividend / Share (Rs.), as of Mar 25, the value is 10.00. This value exceeds the healthy maximum of 3. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 567.22. It has increased from 532.75 (Mar 24) to 567.22, marking an increase of 34.47.
For PBDIT / Share (Rs.), as of Mar 25, the value is 75.07. This value is within the healthy range. It has increased from 70.72 (Mar 24) to 75.07, marking an increase of 4.35.
For PBIT / Share (Rs.), as of Mar 25, the value is 69.18. This value is within the healthy range. It has increased from 61.48 (Mar 24) to 69.18, marking an increase of 7.70.
For PBT / Share (Rs.), as of Mar 25, the value is 76.67. This value is within the healthy range. It has increased from 59.53 (Mar 24) to 76.67, marking an increase of 17.14.
For Net Profit / Share (Rs.), as of Mar 25, the value is 57.79. This value is within the healthy range. It has increased from 44.47 (Mar 24) to 57.79, marking an increase of 13.32.
For PBDIT Margin (%), as of Mar 25, the value is 13.23. This value is within the healthy range. It has decreased from 13.27 (Mar 24) to 13.23, marking a decrease of 0.04.
For PBIT Margin (%), as of Mar 25, the value is 12.19. This value is within the healthy range. It has increased from 11.54 (Mar 24) to 12.19, marking an increase of 0.65.
For PBT Margin (%), as of Mar 25, the value is 13.51. This value is within the healthy range. It has increased from 11.17 (Mar 24) to 13.51, marking an increase of 2.34.
For Net Profit Margin (%), as of Mar 25, the value is 10.18. This value exceeds the healthy maximum of 10. It has increased from 8.34 (Mar 24) to 10.18, marking an increase of 1.84.
For Return on Networth / Equity (%), as of Mar 25, the value is 7.66. This value is below the healthy minimum of 15. It has increased from 6.30 (Mar 24) to 7.66, marking an increase of 1.36.
For Return on Capital Employeed (%), as of Mar 25, the value is 9.13. This value is below the healthy minimum of 10. It has increased from 8.64 (Mar 24) to 9.13, marking an increase of 0.49.
For Return On Assets (%), as of Mar 25, the value is 6.37. This value is within the healthy range. It has increased from 5.23 (Mar 24) to 6.37, marking an increase of 1.14.
For Total Debt / Equity (X), as of Mar 25, the value is 0.02. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.02.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.64. It has increased from 0.63 (Mar 24) to 0.64, marking an increase of 0.01.
For Current Ratio (X), as of Mar 25, the value is 5.23. This value exceeds the healthy maximum of 3. It has decreased from 5.50 (Mar 24) to 5.23, marking a decrease of 0.27.
For Quick Ratio (X), as of Mar 25, the value is 4.72. This value exceeds the healthy maximum of 2. It has decreased from 5.01 (Mar 24) to 4.72, marking a decrease of 0.29.
For Inventory Turnover Ratio (X), as of Mar 25, the value is 1.90. This value is below the healthy minimum of 4. It has decreased from 1.91 (Mar 24) to 1.90, marking a decrease of 0.01.
For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 22.48 (Mar 24) to 0.00, marking a decrease of 22.48.
For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 18.61 (Mar 24) to 0.00, marking a decrease of 18.61.
For Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 77.52 (Mar 24) to 0.00, marking a decrease of 77.52.
For Cash Earning Retention Ratio (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 81.39 (Mar 24) to 0.00, marking a decrease of 81.39.
For Interest Coverage Ratio (X), as of Mar 25, the value is 31.91. This value is within the healthy range. It has decreased from 36.27 (Mar 24) to 31.91, marking a decrease of 4.36.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 21.38. This value is within the healthy range. It has decreased from 23.81 (Mar 24) to 21.38, marking a decrease of 2.43.
For Enterprise Value (Cr.), as of Mar 25, the value is 929.27. It has decreased from 1,342.13 (Mar 24) to 929.27, marking a decrease of 412.86.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.16. This value is within the healthy range. It has decreased from 1.78 (Mar 24) to 1.16, marking a decrease of 0.62.
For EV / EBITDA (X), as of Mar 25, the value is 8.76. This value is within the healthy range. It has decreased from 13.43 (Mar 24) to 8.76, marking a decrease of 4.67.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.78 (Mar 24) to 2.11, marking a decrease of 0.67.
For Retention Ratios (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 77.51 (Mar 24) to 0.00, marking a decrease of 77.51.
For Price / BV (X), as of Mar 25, the value is 1.59. This value is within the healthy range. It has decreased from 2.10 (Mar 24) to 1.59, marking a decrease of 0.51.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 2.11. This value is within the healthy range. It has decreased from 2.78 (Mar 24) to 2.11, marking a decrease of 0.67.
For EarningsYield, as of Mar 25, the value is 0.04. This value is below the healthy minimum of 5. It has increased from 0.02 (Mar 24) to 0.04, marking an increase of 0.02.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of TTK Healthcare Ltd as of June 26, 2025 is: 1,068.06

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of June 26, 2025, TTK Healthcare Ltd is Overvalued by 16.82% compared to the current share price 1,284.00

Intrinsic Value of TTK Healthcare Ltd as of June 26, 2025 is: 1,195.66

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of June 26, 2025, TTK Healthcare Ltd is Overvalued by 6.88% compared to the current share price 1,284.00

Last 5 Year EPS CAGR: 11.95%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a low average Working Capital Days of 0.25, which is a positive sign. The company has higher reserves (396.00 cr) compared to borrowings (29.67 cr), indicating strong financial stability. The company has shown consistent growth in sales (596.00 cr) and profit (94.00 cr) over the years.	The stock has a low average ROCE of 14.17%, which may not be favorable. The stock has a high average Cash Conversion Cycle of 19.67, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in TTK Healthcare Ltd:
1. Net Profit Margin: 10.18%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 9.13% (Industry Average ROCE: 16.65%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 7.66% (Industry Average ROE: 15.19%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 21.38
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 4.72
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 25.5 (Industry average Stock P/E: 103.22)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.02
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

TTK Healthcare Ltd. is a Public Limited Listed company incorporated on 21/05/1958 and has its registered office in the State of Tamil Nadu, India. Company's Corporate Identification Number(CIN) is L24231TN1958PLC003647 and registration number is 003647. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 801.49 Cr. and Equity Capital is Rs. 14.13 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Pharmaceuticals	No 6, Cathedral Road, Chennai (Madras) Tamil Nadu 600086	info@ttkhealthcare.com http://www.ttkhealthcare.com

Management
Name	Position Held
Mr. T T Raghunathan	Executive Chairman
Mr. S Kalyanaraman	Whole Time Director
Dr. T T Mukund	Director
Mr. R K Tulshan	Director
Mr. K Shankaran	Director
Dr.(Mrs.) Vandana R Walvekar	Independent Director
Mr. Girish Rao	Independent Director
Mr. S Balasubramanian	Independent Director
Mr. V Ranganathan	Independent Director
Mr. N Ramesh Rajan	Independent Director

FAQ

What is the intrinsic value of TTK Healthcare Ltd?

TTK Healthcare Ltd's intrinsic value (as of 25 June 2025) is ₹1068.06 — 16.82% lower the current market price of 1,284.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 1,815 Cr. market cap, FY2025-2026 high/low of ₹1,923/991, reserves of 1,051 Cr, and liabilities of 1,281 Cr.

What is the Market Cap of TTK Healthcare Ltd?

The Market Cap of TTK Healthcare Ltd is 1,815 Cr..

What is the current Stock Price of TTK Healthcare Ltd as on 25 June 2025?

The current stock price of TTK Healthcare Ltd as on 25 June 2025 is 1,284.

What is the High / Low of TTK Healthcare Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of TTK Healthcare Ltd stocks is ₹1,923/991.

What is the Stock P/E of TTK Healthcare Ltd?

The Stock P/E of TTK Healthcare Ltd is 25.5.

What is the Book Value of TTK Healthcare Ltd?

The Book Value of TTK Healthcare Ltd is 754.

What is the Dividend Yield of TTK Healthcare Ltd?

The Dividend Yield of TTK Healthcare Ltd is 0.78 %.

What is the ROCE of TTK Healthcare Ltd?

The ROCE of TTK Healthcare Ltd is 9.25 %.

What is the ROE of TTK Healthcare Ltd?

The ROE of TTK Healthcare Ltd is 6.89 %.

What is the Face Value of TTK Healthcare Ltd?

The Face Value of TTK Healthcare Ltd is 10.0.